Desidustat: First Approval

Article Urology & Nephrology

Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D)

Sishir Gang et al.

Summary: This study demonstrates that desidustat is noninferior to epoetin in the treatment of anemia in CKD patients on dialysis and is well-tolerated.

AMERICAN JOURNAL OF NEPHROLOGY (2022)

Add to Collection

Article Urology & Nephrology

Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND)

Dhananjai Agrawal et al.

Summary: Desidustat is non-inferior to darbepoetin in the treatment of anemia due to non-dialysis dependent CKD and it is well-tolerated.

AMERICAN JOURNAL OF NEPHROLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages

Akira Mima

Summary: Anemia is a common feature and complication of chronic kidney disease (CKD), with treatments such as ESAs and HIF-PHIs being widely used. HIF-PHIs show promise in improving renal anemia treatment by lowering hepcidin levels, modulating iron metabolism, reducing inflammation, and oxidative stress. However, further studies are needed to evaluate the long-term effects and potential risks of HIF-PHIs in clinical practice.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

Add to Collection

Article Urology & Nephrology